A Study to Test the Effect of Empagliflozin in Patients Who Are in Hospital for Acute Heart Failure

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 530 participants.

Also called NCT04157751

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 530 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04157751
  • EudraCT 2019-002946-19
Other papers using this trial's data
  • Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial Circulation, 2022-07-26 DOI, PubMed 35377706, PMC9311476 In the PMC Open Access subset under CC BY.
  • Empagliflozin in De Novo vs Acute Decompensated Chronic Heart Failure: A Prespecified Analysis From EMPULSE JACC. Heart failure, 2026-08 DOI, PubMed 41793401
  • Mineralocorticoid receptor antagonist use and the effects of empagliflozin on clinical outcomes in patients admitted for acute heart failure: Findings from EMPULSE European journal of heart failure, 2023-10 DOI, PubMed 37540060
  • The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial Nature medicine, 2022-03 DOI, PubMed 35228754, PMC8938265 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Belgium, Canada, China, Czechia, Denmark, Germany, Hungary, Italy, Japan, Netherlands, Norway, Poland, Spain, Sweden (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04157751. Randomized; double masking; primary purpose treatment. Start 2020-05-18 (actual); primary completion 2021-05-28 (actual). Results posted on 2022-06-06.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Test the Effect of Empagliflozin in Patients Who Are in Hospital for Acute Heart Failure
Condition
Heart Failure
Intervention (Drug)
Empagliflozin
Intervention (Drug)
Placebo to Empagliflozin
Lead sponsor
Boehringer Ingelheim (class: industry)
Collaborator
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct04157751
Content hash
bc4cb3157b204d257ffa6686759560bf7b5baac8b539231f100fe4b6973b834a